Insights & Analysis
Practical guidance on PBM audits, federal investigations, compounding defense, DEA enforcement, telehealth compliance, and the regulatory pressures facing pharmacies and providers nationwide.
More articles — Page 43
Page 43 of 114 · 1029 articles
PBM Invoice Audit: Proving Your Purchases
Wholesaler invoice reconciliation, shortage findings, and extrapolation: how PBM audits weigh a pharmacy's proof of purchase, and…
Mid-Level Practitioner Prescribing Authority Limits
State law, not DEA registration, sets a mid-level practitioner's prescribing authority. What pharmacists and practices need to ver…
Reactivating a Deactivated Medicare Billing Number
Deactivation is not revocation. What triggers a deactivated Medicare billing number, how to reactivate it, and the claims gap that…
Memoranda of Agreement With DEA
What a DEA Memorandum of Agreement resolves, the terms it commonly imposes, and what a breach of those terms means for the registr…
Telehealth Partnership Models for Compounding Pharmacies
How telehealth platform fees to compounding pharmacies can cross into Anti-Kickback Statute exposure, and how to structure the agr…
Marketing Claims for Compounded Drugs
FDA and FTC apply separate rules to compounded drug marketing, and a single ad can trigger both. What claims are permitted, and wh…
Telehealth Practice and Out-of-State Board Complaints
A telehealth visit can put a physician under a medical board in the state where the patient was located, with reciprocal risk to t…
Telehealth Fraud in Medicare Advantage Plans
How telehealth health risk assessments feed Medicare Advantage risk adjustment, the DOJ and OIG enforcement pattern, and where pro…
Telehealth Documentation Standards That Survive Review
What a telehealth visit note needs to survive a payer or program-integrity audit: modality, location, time, and consent documentat…